1. Modified Predictive Model and Nomogram by Incorporating Prebiopsy Biparametric Magnetic Resonance Imaging With Clinical Indicators for Prostate Biopsy Decision Making
- Author
-
Jin-feng Pan, Rui Su, Jian-zhou Cao, Zhen-ya Zhao, Da-wei Ren, Sha-zhou Ye, Rui-da Huang, Zhu-lei Tao, Cheng-ling Yu, Jun-hui Jiang, and Qi Ma
- Subjects
Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Prostate biopsy ,biparametric MRI (Bp-MRI) ,prostate-specific antigen density (PSAD) ,Prostate cancer ,Prostate ,medicine ,prostate-specific antigen ,prostate biopsy ,RC254-282 ,Original Research ,medicine.diagnostic_test ,business.industry ,Area under the curve ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Rectal examination ,Nomogram ,prostate cancer ,medicine.disease ,Prostate-specific antigen ,medicine.anatomical_structure ,Oncology ,PIRADS score ,Radiology ,business - Abstract
PurposeThe purpose of this study is to explore the value of combining bpMRI and clinical indicators in the diagnosis of clinically significant prostate cancer (csPCa), and developing a prediction model and Nomogram to guide clinical decision-making.MethodsWe retrospectively analyzed 530 patients who underwent prostate biopsy due to elevated serum prostate specific antigen (PSA) levels and/or suspicious digital rectal examination (DRE). Enrolled patients were randomly assigned to the training group (n = 371, 70%) and validation group (n = 159, 30%). All patients underwent prostate bpMRI examination, and T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI) sequences were collected before biopsy and were scored, which were respectively named T2WI score and DWI score according to Prostate Imaging Reporting and Data System version 2 (PI-RADS v.2) scoring protocol, and then PI-RADS scoring was performed. We defined a new bpMRI-based parameter named Total score (Total score = T2WI score + DWI score). PI-RADS score and Total score were separately included in the multivariate analysis of the training group to determine independent predictors for csPCa and establish prediction models. Then, prediction models and clinical indicators were compared by analyzing the area under the curve (AUC) and decision curves. A Nomogram for predicting csPCa was established using data from the training group.ResultsIn the training group, 160 (43.1%) patients had prostate cancer (PCa), including 128 (34.5%) with csPCa. Multivariate regression analysis showed that the PI-RADS score, Total score, f/tPSA, and PSA density (PSAD) were independent predictors of csPCa. The prediction model that was defined by Total score, f/tPSA, and PSAD had the highest discriminatory power of csPCa (AUC = 0.931), and the diagnostic sensitivity and specificity were 85.1% and 87.5%, respectively. Decision curve analysis (DCA) showed that the prediction model achieved an optimal overall net benefit in both the training group and the validation group. In addition, the Nomogram predicted csPCa revealed good estimation when compared with clinical indicators.ConclusionThe prediction model and Nomogram based on bpMRI and clinical indicators exhibit a satisfactory predictive value and improved risk stratification for csPCa, which could be used for clinical biopsy decision-making.
- Published
- 2021
- Full Text
- View/download PDF